Precirix
Dissolution or liquidationThe KBO register records for Precirix the legal situation: dissolution or liquidation; this is today's state according to the register itself, which carries no start date. Dissolved on 17-12-2025, in liquidation; liquidator: QUINZ.
Summary
The 2025 annual accounts show negative equity (-€15.7m) and a net result of -€15.7m.
Signals
Three signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year -€15.7m
neutral · Latest accounts filed on time
The financial year that closed on 17-12-2025 was due by 17-07-2026 and was filed on 12-05-2026, 66 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
66 d early
2024
21 d early
2023
69 d early
2022
67 d early
2021
67 d early
2020
60 d early
2019
72 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 60 days before the deadline; the sector median for financial year 2024 is 13 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (1)
History
Precirix was incorporated on 15 October 2014, with a starting capital of EUR 61,500.12 Between 2015 and 2022 the capital was increased 7 times, most recently to EUR 22 million.345 The registered office moved to Jette in 2016 and to Brussel in 2023.67 The name was changed to Precirix in 2020 and to Precirix, in vereffening in 2026.89 The board currently has 5 members; BOS Jasper Marnix has served longest, since 2022.5 Total assets fell from EUR 11 million in 2018 to EUR 3.9 million in 2025 and headcount from 4 to 20.6 full-time equivalents.10 In 2025 the company was dissolved and put into liquidation.9
- 1Crossroads Bank for Enterprises
- 2Belgian State Gazette, 24-10-2014
- 3Belgian State Gazette, 10-06-2015
- 4Belgian State Gazette, 16-07-2020
- 5Belgian State Gazette, 03-03-2022
- 6Belgian State Gazette, 29-06-2016
- 7Belgian State Gazette, 03-01-2023
- 8Belgian State Gazette, 02-10-2020
- 9Belgian State Gazette, 20-01-2026
- 10National Bank, annual accounts 2018 and 2025
Go further with this company
What became of the directors' other companies?Supplier due diligence Who ran this company, and where was it based, on a date before the end?Company as of a date How is this company connected to another party?Network investigator How is the Research and development on biotechnology sector doing?Sector figures
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, abbreviated schema
Equity
-€15.7m
2024 · €59,605
Total assets
€3.9m▼ 73.4%
2024 · €14.5m
Net result
-€15.7m▼ 62.8%
2024 · -€9.7m
Working capital
-€13.3m
2024 · €6.2m
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Operating result-€10.7m▼ 56.6%-€17.5m▼ 63.4%-€16.4m▲ 6.4%-€9.5m▲ 42.2%-€12.0m▼ 26.9%
Net result-€10.3mbelow the sector's middle half▼ 67.1%-€17.0mbelow the sector's middle half▼ 64.1%-€15.2mbelow the sector's middle half▲ 10.2%-€9.7mbelow the sector's middle half▲ 36.6%-€15.7mbelow the sector's middle half▼ 62.8%
Equity€1.9mwithin the sector's middle half▼ 84.4%€24.9mabove the sector's middle half▲ 1,210%€9.7mabove the sector's middle half▼ 61.0%€59,605below the sector's middle half▼ 99.4%-€15.7mbelow the sector's middle half
Total assets€4.0mwithin the sector's middle half▼ 70.2%€28.3mabove the sector's middle half▲ 598%€11.9mabove the sector's middle half▼ 57.9%€14.5mabove the sector's middle half▲ 21.6%€3.9mwithin the sector's middle half▼ 73.4%
Debt€2.1m▲ 59.9%€3.3m▲ 54.6%€2.2m▼ 34.0%€14.4m▲ 559%€17.7m▲ 22.7%
Working capital€1.9mwithin the sector's middle half▼ 85.0%€22.9mabove the sector's middle half▲ 1,099%€7.4mabove the sector's middle half▼ 67.5%€6.2mabove the sector's middle half▼ 16.1%-€13.3mbelow the sector's middle half
Solvency47.0%within the sector's middle half▼ 43.1pp88.3%above the sector's middle half▲ 41.2pp81.6%above the sector's middle half▼ 6.6pp0.4%below the sector's middle half▼ 81.2pp-406.7%below the sector's middle half▼ 407.1pp
Current ratio2.11within the sector's middle half▼ 17.028.02above the sector's middle half▲ 5.914.46within the sector's middle half▼ 3.562.01within the sector's middle half▼ 2.450.22below the sector's middle half▼ 1.78
Return on assets (ROA)-255.3%below the sector's middle half▼ 209.8pp-60.0%below the sector's middle half▲ 195.3pp-127.9%below the sector's middle half▼ 67.8pp-66.7%below the sector's middle half▲ 61.2pp-408.2%below the sector's middle half▼ 341.5pp
Staff (FTE)15.1within the sector's middle half▲ 33.6%21.3within the sector's middle half▲ 41.1%28.9within the sector's middle half▲ 35.7%21.1within the sector's middle half▼ 27.0%20.6above the sector's middle half▼ 2.4%
above
within
below
the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Why a figure moved sharply
- 2022 Equity +1,210%, Total assets +598% on 2021. Capital increase of €9,777,309 (Official Gazette 03-03-2022).
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €12.0m in 2025 against €9.5m in 2024; the loss grows.
Key figures and ratios
EBITDA
-€10.0m▼
2024 · -€4.0m
Cash flow
-€13.7m▼
2024 · -€4.2m
Debt to equity
-1.13
Interest coverage
-7.62▼
2024 · -7.45
Debt ≤ 1 year
€17.1m▲
2024 · €6.2m
Debt > 1 year
€0▼
2024 · €7.7m
Income taxes
€2.5m▲
2024 · -€262,591
Staff costs
€2.6m▲
2024 · €2.6m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Remuneration, social security and pensions62 | €1.5m | €2.2m | €2.9m | €2.6m | €2.6m | ▲ 2.7% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €9.5m | €12.8m | €12.7m | €5.5m | €2.0m | ▼ 62.9% |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | - | - | - | - | €1.8m | - |
| Other operating charges640/8 | €4,283 | €4,107 | €3,915 | €20,272 | €14,366 | ▼ 29.1% |
| Non-recurring operating charges66A | - | €1.3m | €0 | €7,484 | €0 | ▼ 100% |
| Gross operating margin9900 | €287,397 | -€1.3m | -€741,851 | -€1.4m | -€5.5m | ▼ 292% |
| Operating profit (loss)9901 | -€10.7m | -€17.5m | -€16.4m | -€9.5m | -€12.0m | ▼ 26.9% |
| Financial income75/76B | €796 | €1,462 | €201,060 | €100,520 | €75,886 | ▼ 24.5% |
| Recurring financial income75 | €796 | €1,462 | €201,060 | €100,520 | €75,886 | ▼ 24.5% |
| Financial charges65/66B | €53,926 | €70,532 | €6,411 | €537,379 | €1.3m | ▲ 144% |
| Recurring financial charges65 | €53,926 | €70,532 | €6,411 | €537,379 | €1.3m | ▲ 144% |
| Profit (loss) for the period before taxes9903 | -€10.8m | -€17.6m | -€16.2m | -€9.9m | -€13.3m | ▼ 33.7% |
| Income taxes67/77 | -€451,520 | -€650,981 | -€1.0m | -€262,591 | €2.5m | ▲ 1,035% |
| Profit (loss) for the period9904 | -€10.3m | -€17.0m | -€15.2m | -€9.7m | -€15.7m | ▼ 62.8% |
| Profit (loss) for the period to be appropriated9905 | -€10.3m | -€17.0m | -€15.2m | -€9.7m | -€15.7m | ▼ 62.8% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €4.0m | €28.3m | €11.9m | €14.5m | €3.9m | ▼ 73.4% |
| Fixed assets21/28 | €413,330 | €2.1m | €2.3m | €2.0m | €0 | ▼ 100% |
| Tangible fixed assets22/27 | €405,455 | €2.1m | €2.3m | €2.0m | €0 | ▼ 100% |
| Plant, machinery and equipment23 | €363,286 | €1.3m | €1.6m | €1.4m | €0 | ▼ 100% |
| Furniture and vehicles24 | €42,169 | €141,815 | €116,039 | €90,382 | €0 | ▼ 100% |
| Other tangible fixed assets26 | - | €632,091 | €639,993 | €562,114 | €0 | ▼ 100% |
| Financial fixed assets28 | €7,875 | €0 | - | - | - | - |
| Current assets29/58 | €3.6m | €26.2m | €9.6m | €12.4m | €3.9m | ▼ 69.1% |
| Amounts receivable after more than one year29 | - | - | €2.7m | €2.8m | €0 | ▼ 100% |
| Other amounts receivable291 | - | - | €2.7m | €2.8m | €0 | ▼ 100% |
| Amounts receivable within one year40/41 | €1.8m | €2.5m | €427,385 | €477,345 | €778,468 | ▲ 63.1% |
| Trade receivables40 | - | - | - | - | €117 | - |
| Other amounts receivable41 | €1.8m | €2.5m | €427,385 | €477,345 | €778,351 | ▲ 63.1% |
| Current investments50/53 | - | - | €3.0m | €8.3m | €0 | ▼ 100% |
| Cash at bank and in hand54/58 | €1.8m | €23.6m | €3.5m | €865,734 | €3.0m | ▲ 248% |
| Deferred charges and accrued income490/1 | €49,594 | €65,448 | €28,653 | €66,347 | €62,987 | ▼ 5.1% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €4.0m | €28.3m | €11.9m | €14.5m | €3.9m | ▼ 73.4% |
| Equity10/15 | €1.9m | €24.9m | €9.7m | €59,605 | -€15.7m | ▼ 26,380% |
| Contributions10/11 | €26.8m | €66.8m | €66.8m | €66.8m | €66.8m | = |
| Capital10 | €11.8m | €21.5m | €21.5m | €21.5m | €21.5m | = |
| Issued capital100 | €11.8m | €21.5m | €21.5m | €21.5m | €21.5m | = |
| Outside capital11 | €15.1m | €45.3m | €45.3m | €45.3m | €45.3m | = |
| Share premium1100/10 | €15.1m | €45.3m | €45.3m | €45.3m | €45.3m | = |
| Profit (loss) carried forward14 | -€24.9m | -€41.9m | -€57.1m | -€66.8m | -€82.5m | ▼ 23.5% |
| Provisions and deferred taxes16 | - | - | - | - | €1.8m | - |
| Provisions for liabilities and charges160/5 | - | - | - | - | €1.8m | - |
| Other liabilities and charges164/5 | - | - | - | - | €1.8m | - |
| Amounts payable17/49 | €2.1m | €3.3m | €2.2m | €14.4m | €17.7m | ▲ 22.7% |
| Amounts payable after more than one year17 | - | - | - | €7.7m | €0 | ▼ 100% |
| Financial debts170/4 | - | - | - | €7.7m | €0 | ▼ 100% |
| Amounts payable within one year42/48 | €1.7m | €3.3m | €2.2m | €6.2m | €17.1m | ▲ 176% |
| Current portion of amounts payable after more than one year42 | - | - | - | €5.0m | €15.8m | ▲ 215% |
| Trade debts44 | €1.4m | €2.8m | €1.6m | €767,550 | €699,300 | ▼ 8.9% |
| Suppliers440/4 | €1.4m | €2.8m | €1.6m | €767,550 | €699,300 | ▼ 8.9% |
| Taxes, remuneration and social security45 | €362,157 | €501,126 | €520,800 | €436,903 | €656,720 | ▲ 50.3% |
| Taxes450/3 | €11,339 | €17,653 | €20,486 | €15,634 | €172,068 | ▲ 1,001% |
| Remuneration and social security454/9 | €350,818 | €483,473 | €500,314 | €421,270 | €484,651 | ▲ 15.0% |
| Accrued charges and deferred income492/3 | €421,510 | €53,146 | €34,907 | €529,986 | €572,836 | ▲ 8.1% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€10.3m | -€17.0m | -€15.2m | -€9.7m | -€15.7m | ▼ 62.8% |
| + Depreciation and write-downs630 | €9.5m | €12.8m | €12.7m | €5.5m | €2.0m | ▼ 62.9% |
| Operating cash flow (approximation) | -€852,094 | -€4.2m | -€2.5m | -€4.2m | -€13.7m | ▼ 228% |
| Investment in fixed assets (approximation) | - | -€14.5m | -€13.0m | -€5.2m | €0 | ▲ 100% |
| Change in cash | - | €21.8m | -€20.1m | -€2.6m | €2.1m | ▲ 183% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2026
12-05
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
20-01
State Gazette act
Resignations & appointments · End & cessationResignations: Cetium AS, Mesonax Ltd and 6 others · Appointment: QUINZ (liquidator) · Permanent representatives: THIBAUT Klaas, Ramdahl Thomas and 2 others20 facts ▸
State Gazette act
Resignations & appointments · End & cessation
Resignations: Cetium AS, Mesonax Ltd and 6 others · Appointment: QUINZ (liquidator) · Permanent representatives: THIBAUT Klaas, Ramdahl Thomas and 2 others20 facts ▸
- General meeting, 17-12-2025
- Statutes amendment
- Director discharge, Precirix
- Dissolution, 17-12-2025
- Liquidation, 17-12-2025
- Director resignation, Cetium AS (director)
- Director resignation, Mesonax Ltd (director)
- Director resignation, Pharmetis (director)
- Director resignation, Bos Jasper (director)
- Director resignation, Burkov Ivan (director)
- Director resignation, Hansen Camilla Petrycer (director)
- Director resignation, Steen Marten (director)
- +8 further facts in this act
2025
10-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
15-05
State Gazette act
Statutes amendmentShare issue · Power of attorney5 facts ▸
State Gazette act
Statutes amendment
Share issue · Power of attorney5 facts ▸
- General meeting, 30-04-2024
- Statutes amendment
- Share issue, Actualisering van het aantal inschrijvingsrechten uitgegeven door de Vennootschap
- Power of attorney, Precirix
- Power of attorney, Precirix
06-03
State Gazette act
Resignation: Sabine Dandiguian (board director and member of the remuneration/hiring committee)2 facts ▸
State Gazette act
Resignation: Sabine Dandiguian (board director and member of the remuneration/hiring committee)
2 facts ▸
- Board meeting, 10-12-2024
- Director resignation, Sabine Dandiguian (board director and member of the remuneration/hiring committee)
2024
28-11
State Gazette act
MiscellaneousApproval · Subscription right issue · Capital increase4 facts ▸
State Gazette act
Miscellaneous
Approval · Subscription right issue · Capital increase4 facts ▸
- General meeting, 20-11-2024
- Approval, 20-11-2024
- Subscription right issue, Lening Inschrijvingsrechten, 12
- Capital increase
13-11
State Gazette act
Appointments: Pharmetis Sàrl, Camilla Petrycer Hansen and Ivan BurkovPermanent representatives: Thomas Plitz and Thomas Ramdahl · Reappointments: Mårten Steen, Michaël Vlemmix and 2 others10 facts ▸
State Gazette act
Appointments: Pharmetis Sàrl, Camilla Petrycer Hansen and Ivan Burkov
Permanent representatives: Thomas Plitz and Thomas Ramdahl · Reappointments: Mårten Steen, Michaël Vlemmix and 2 others10 facts ▸
- General meeting, 07-05-2024
- Director appointment, Pharmetis Sàrl (vennootschapsbestuurder)
- Permanent representative, Thomas Plitz
- Director appointment, Camilla Petrycer Hansen (a bestuurder voor novo)
- Director reappointment, Mårten Steen (a bestuurder voor healthcap)
- Director reappointment, Michaël Vlemmix (a bestuurder voor gimv)
- Director appointment, Ivan Burkov (b bestuurder voor inkef)
- Director reappointment, Cetium AS (independent director)
- Permanent representative, Thomas Ramdahl
- Auditor reappointment, BDO
23-05
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
20-03
State Gazette act
Resignations: Hasseltberg BV, Dimitrios Mantzilas and Josie GaytonAppointments: Dimitrios Mantzilas, Josie Gayton and Pharmetis Sàrl · Permanent representative: Tom Plitz · Power of attorney13 facts ▸
State Gazette act
Resignations: Hasseltberg BV, Dimitrios Mantzilas and Josie Gayton
Appointments: Dimitrios Mantzilas, Josie Gayton and Pharmetis Sàrl · Permanent representative: Tom Plitz · Power of attorney13 facts ▸
- Board meeting, 01-02-2024
- Director resignation, Hasseltberg BV (chief executive officer / dagelijks bestuur)
- Director appointment, Dimitrios Mantzilas (cto / gezamenlijk dagelijks bestuur)
- Director appointment, Josie Gayton (cdo / gezamenlijk dagelijks bestuur)
- Power of attorney, Freshfields Bruckhaus Deringer LLP
- Board meeting, 28-02-2024
- Director resignation, Hasseltberg BV (director)
- Director appointment, Pharmetis Sàrl (director)
- Permanent representative, Tom Plitz
- Director appointment, Pharmetis Sàrl (managing director)
- Director resignation, Dimitrios Mantzilas (gezamenlijk dagelijks bestuur)
- Director resignation, Josie Gayton (gezamenlijk dagelijks bestuur)
- +1 further facts in this act
07-03
State Gazette act
Statutes amendmentApproval · Net-asset statement · Share issue12 facts ▸
State Gazette act
Statutes amendment
Approval · Net-asset statement · Share issue12 facts ▸
- General meeting, 19-02-2024
- Approval
- Net-asset statement, 31-12-2023
- Share issue, 17, Lening Inschrijvingsrechten
- Capital increase
- Capital, €21.529.954,3
- Statutes amendment
- Approval, Converteerbare Leningsovereenkomst, 5.000.000,00 EUR
- Approval, Afstand van het voorkeurrecht
- Approval, Inschrijving op de Lening Inschrijvingsrechten
- Statute, Investor nomination rights: FORBION, INKEF, JEITO nominate B Bestuurders; GIMV, HEALTHCAP, NOVO nominate A Bestuurders; A and Nieuwe Investeerders jointly nomin…
- Representation, Raad van Bestuur handelend door twee (2) gezamenlijk optredende Bestuurders, alsook door de Gedelegeerd Bestuurder, alleen handelend, binnen de perken van het d…
2023
25-05
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
03-01
State Gazette act
Registered officeRegistered-office move · Power of attorney3 facts ▸
State Gazette act
Registered office
Registered-office move · Power of attorney3 facts ▸
- Board meeting, 08-09-2022
- Registered-office move, Burgemeester Etienne Demunterlaan 3 in 1090 Brussel, België
- Power of attorney, Freshfields Bruckhaus Deringer LLP
Show earlier events
2022
31-12
Financial
Weakest financial yearnet -€17.0m
Net result drops to -€17.0m, the lowest in the series.
31-12
Financial
Liquidity quadruplescurrent ratio 8.02
Current ratio from 2.11 to 8.02.
31-12
Financial
Equity above €10mEq €24.9m ▲1,210%
Equity rises from €1.9m to €24.9m.
10-11
State Gazette act
Appointment: Mesonax Ltd. (independent director)Permanent representative: Simon Sturge3 facts ▸
State Gazette act
Appointment: Mesonax Ltd. (independent director)
Permanent representative: Simon Sturge3 facts ▸
- General meeting, 12-10-2022
- Director appointment, Mesonax Ltd. (independent director)
- Permanent representative, Simon Sturge
25-05
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
03-03
State Gazette act
Resignations: TAKKE Christina, HAMMER Ohad and BAUDHUIN Jean-LouisAppointments: BOTTI Simone, MOUMDJIAN (geh. DANDIGUIAN) Sabine Kohar and BOS Jasper Marnix · Capital increase · Bank account28 facts ▸
State Gazette act
Resignations: TAKKE Christina, HAMMER Ohad and BAUDHUIN Jean-Louis
Appointments: BOTTI Simone, MOUMDJIAN (geh. DANDIGUIAN) Sabine Kohar and BOS Jasper Marnix · Capital increase · Bank account28 facts ▸
- General meeting, 28-02-2022
- Capital increase, €9.777.308,89
- Bank account, Bank J.Van Breda & C° NV
- Share issue, 80, Preferente B Anti-dilutie Inschrijvingsrechten
- Share issue, 80, Vrijwaring Inschrijvingsrechten
- Share issue, 27190, ESOP Inschrijvingsrechten op winstbewijzen
- Share cancellation
- Share cancellation
- Statutes amendment
- Capital, €21.529.954,3
- Director resignation, TAKKE Christina (director)
- Director resignation, HAMMER Ohad (director)
- +16 further facts in this act
2021
19-07
State Gazette act
Reappointment: BDO BEDRIJFSREVISOREN (statutory auditor)Permanent representative: Ruth Devenyns3 facts ▸
State Gazette act
Reappointment: BDO BEDRIJFSREVISOREN (statutory auditor)
Permanent representative: Ruth Devenyns3 facts ▸
- General meeting, 17-05-2021
- Auditor reappointment, BDO BEDRIJFSREVISOREN
- Permanent representative, Ruth Devenyns
01-06
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
31-12
Financial
Liquidity doublescurrent ratio 19.13
Current ratio from 8.29 to 19.13; short-term debt falls from €759,976 to €703,898.
31-12
Financial
Equity above €10mEq €12.2m ▲119%
Equity rises from €5.6m to €12.2m.
02-10
State Gazette act
Statutes amendmentName change · Capital · Power of attorney5 facts ▸
State Gazette act
Statutes amendment
Name change · Capital · Power of attorney5 facts ▸
- General meeting, 21-09-2020
- Name change, Precirix
- Statutes amendment
- Capital, €11.752.645,41
- Power of attorney, Freshfields Bruckhaus Deringer LLP
16-07
State Gazette act
Capital & shares · Statutes amendmentCapital increase · Share issue · Bank account7 facts ▸
State Gazette act
Capital & shares · Statutes amendment
Capital increase · Share issue · Bank account7 facts ▸
- General meeting, 14-11-2018
- Capital increase, €4.705.219,45
- Share issue, Preferente A Aandelen, 64165
- Bank account, Bank J.Van Breda & C° NV, BE76 6451 0335 9595
- Capital, €11.752.645,41
- Statutes amendment
- Power of attorney, Freshfields Bruckhaus Deringer LLP
20-05
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
04-02
State Gazette act
Resignation: Karl Nägler (director)Appointment: Michaël Vlemmix (gimv bestuurder)3 facts ▸
State Gazette act
Resignation: Karl Nägler (director)
Appointment: Michaël Vlemmix (gimv bestuurder)3 facts ▸
- General meeting, 21-10-2019
- Director resignation, Karl Nägler (director)
- Director appointment, Michaël Vlemmix (gimv bestuurder)
2019
21-05
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
24-04
State Gazette act
Appointment: Cetium AS (non-executive director)Permanent representative: Thomas Ramdahl3 facts ▸
State Gazette act
Appointment: Cetium AS (non-executive director)
Permanent representative: Thomas Ramdahl3 facts ▸
- General meeting, 02-04-2019
- Director appointment, Cetium AS (non-executive director)
- Permanent representative, Thomas Ramdahl
2018
04-12
State Gazette act
Resignations: BOONEN Jacobus, RAES Geert and 6 othersAppointments: Hasseltberg, BAUDHUIN Jean Louis Marie Clément and 6 others · Permanent representative: DEVENYNS Ruth Martine Yvonne · Capital increase37 facts ▸
State Gazette act
Resignations: BOONEN Jacobus, RAES Geert and 6 others
Appointments: Hasseltberg, BAUDHUIN Jean Louis Marie Clément and 6 others · Permanent representative: DEVENYNS Ruth Martine Yvonne · Capital increase37 facts ▸
- General meeting, 14-11-2018
- Capital increase, €4.033.150
- Bank account, BE50 6451 0293 4718
- Share issue, 75, Preferente Klasse A Anti-dilutie Warrants
- Share issue, 64165, Preferente Klasse A Second Closing Warrants
- Share issue, 42776, Preferente Klasse A Third Closing Warrants
- Share issue, 22550, ESOP Warrants op winstbewijzen
- Share issue, 22550, winstbewijzen
- Share issue, 22550, conversie van winstbewijzen
- Statutes amendment
- Capital, €7.047.425,96
- Director resignation, BOONEN Jacobus (director)
- +25 further facts in this act
04-07
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
18-01
State Gazette act
Appointment: Hasseltberg (day-to-day manager)Permanent representative: Ruth DEVENYNS3 facts ▸
State Gazette act
Appointment: Hasseltberg (day-to-day manager)
Permanent representative: Ruth DEVENYNS3 facts ▸
- Board meeting, 11-10-2017
- Director appointment, Hasseltberg (day-to-day manager)
- Permanent representative, Ruth DEVENYNS
2017
30-11
State Gazette act
Appointment: Hasseltberg (director)Permanent representative: DEVENYNS Ruth Martine Yvonne · Capital increase · Share issue7 facts ▸
State Gazette act
Appointment: Hasseltberg (director)
Permanent representative: DEVENYNS Ruth Martine Yvonne · Capital increase · Share issue7 facts ▸
- General meeting, 27-10-2017
- Capital increase, €497.925,31
- Share issue, 5000, B
- Bank account, 24-10-2017
- Capital, €3.014.275,96
- Director appointment, Hasseltberg (director)
- Permanent representative, DEVENYNS Ruth Martine Yvonne
04-07
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
16-06
State Gazette act
Appointment: MAJOIE Jérome Jean-Ghislain Hugues (director)Approval · Statutes amendment · Capital increase12 facts ▸
State Gazette act
Appointment: MAJOIE Jérome Jean-Ghislain Hugues (director)
Approval · Statutes amendment · Capital increase12 facts ▸
- General meeting, 24-05-2017
- Approval, 24-05-2017
- Statutes amendment
- Statutes amendment
- Capital increase, €995.850,65
- Share issue, 25, 9975
- Bank account, Bank J. Van Breda & C°
- Capital, €2.516.350,65
- Director appointment, MAJOIE Jérome Jean-Ghislain Hugues (director)
- Power of attorney, ATALEX bvba
- Waiver of preemptive right, Vrije Universiteit Brussel
- Waiver of preemptive right, GROWTH FACTOR
2016
29-06
State Gazette act
Resignation: GROWTH FACTOR (director)Appointment: Jan WILLEMSE (managing director) · Mandate compensation · Registered-office move5 facts ▸
State Gazette act
Resignation: GROWTH FACTOR (director)
Appointment: Jan WILLEMSE (managing director) · Mandate compensation · Registered-office move5 facts ▸
- Board meeting, 13-05-2016
- Director resignation, GROWTH FACTOR (director)
- Director appointment, Jan WILLEMSE (managing director)
- Mandate compensation, Jan WILLEMSE
- Registered-office move, Greenland Office Park, Burgemeester Etienne de Munterlaan, 1 1090 Jette
2015
29-07
State Gazette act
Capital & shares · Statutes amendmentCapital · Capital increase · Waiver of preemptive right7 facts ▸
State Gazette act
Capital & shares · Statutes amendment
Capital · Capital increase · Waiver of preemptive right7 facts ▸
- General meeting, 09-07-2015
- Statutes amendment
- Capital, €120.500
- Capital increase, €350.000
- Waiver of preemptive right, All shareholders individually waived their pre-emptive right to subscribe to the new capital shares
- Power of attorney, BAUDHUIN Jean Louis Marie Clément
- Share structure, 12050, 0
84.3% of this act was read; anything after the cut is not in this list.Read the act at the Belgisch Staatsblad ↗
10-06
State Gazette act
Capital & shares · Statutes amendmentCapital increase · Share issue · Capital6 facts ▸
State Gazette act
Capital & shares · Statutes amendment
Capital increase · Share issue · Capital6 facts ▸
- General meeting, 28/05/2015
- Capital increase, €59.000
- Share issue, A, 5900
- Capital, €120.500
- Statutes amendment
- Power of attorney, RAES Geert Mark
2014
24-10
State Gazette act
IncorporationAppointments: GROWTH FACTOR, RAES Geert Mark and 4 others · Permanent representative: CAMUSOT Ludwig · Founding capital15 facts ▸
State Gazette act
Incorporation
Appointments: GROWTH FACTOR, RAES Geert Mark and 4 others · Permanent representative: CAMUSOT Ludwig · Founding capital15 facts ▸
- Incorporation, 14-10-2014
- Founding capital, €61.500
- Bank account, BE98 6451 0488 2293
- General meeting, 14-10-2014
- Director appointment, GROWTH FACTOR (director)
- Director appointment, RAES Geert Mark (director)
- Director appointment, LAHOUTTE Tony Maurice (director)
- Director appointment, DEVOOGDT Nick Mark (director)
- Director appointment, D'HUYVETTER Matthias Bruno Líeven (director)
- Director appointment, DE VOS Jens (director)
- Board meeting, 14-10-2014
- Director appointment, GROWTH FACTOR (managing director and chair of the board)
- +3 further facts in this act
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
24 of 24 acts read
Directors · office · real estate
Directors
4 directors, 1 in day-to-day management, last change in 2025
Board 4
BOS Jasper Marnix
CurrentDirector · since 28-02-2022
BOTTI Simone
CurrentDirector · since 28-02-2022
MOUMDJIAN (geh. DANDIGUIAN) Sabine Kohar
CurrentDirector · since 28-02-2022
Pharmetis Sàrl
CurrentDirector · since 28-02-2024 · Legal entity · perm. rep.: Tom Plitz
10 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
D'HUYVETTER Matthias Bruno Líeven
Not recently confirmedDirector · since 14-10-2014
DE VOS Jens
Not recently confirmedDirector · since 14-10-2014
DEVOOGDT Nick Mark
Not recently confirmedDirector · since 14-10-2014
GROWTH FACTOR
Not recently confirmedDirector · since 14-10-2014 · Private limited company · perm. rep.: CAMUSOT Ludwig
RAES Geert Mark
Not recently confirmedDirector · since 14-10-2014
MAJOIE Jérome Jean-Ghislain Hugues
Not recently confirmedDirector · since 21-02-2017
HASSELTBERG
Not recently confirmedDirector · since 27-10-2017 · Private limited company · perm. rep.: DEVENYNS Ruth Martine Yvonne
BAUDHUIN Jean Louis Marie Clément
Not recently confirmedGewone aandelen bestuurder · since 14-11-2018
DØSSING Morten Graugaard
Not recently confirmedNovo bestuurder · since 14-11-2018
Hasseltberg
Not recently confirmedManager bestuurder · since 14-11-2018 · Legal entity · perm. rep.: Ruth DEVENYNS
Day-to-day management 1
Pharmetis Sàrl
CurrentManaging director · since 28-02-2024 · Legal entity · perm. rep.: Tom Plitz
1 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
GROWTH FACTOR
Not recently confirmedManaging director and chair of the board · since 14-10-2014 · Private limited company · perm. rep.: CAMUSOT Ludwig
Permanent representatives 2
Tom Plitz
CurrentPermanent representative · since 28-02-2024 · for Pharmetis Sàrl
THIBAUT Klaas
CurrentPermanent representative · since 17-12-2025 · for QUINZ
2 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
CAMUSOT Ludwig
Not recently confirmedPermanent representative · since 14-10-2014 · for GROWTH FACTOR
Ruth DEVENYNS
Not recently confirmedPermanent representative · since 14-11-2018 · for Hasseltberg
Statutory auditor 1
BDO
CurrentAuditor · since 14-11-2018
Other functions 2
Pharmetis Sàrl
CurrentVennootschapsbestuurder · since 28-02-2024 · Legal entity · perm. rep.: Tom Plitz
QUINZ
CurrentLiquidator · since 17-12-2025 · Private limited company · perm. rep.: THIBAUT Klaas
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ.
See the function holders in the CBE →
Not every act has been read: a resignation may be missing here
1 act was read only in part. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Jette · 1 establishment unit since 2014
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Burgemeester Etienne Demunterl. 31090 Jette1 establishment unit
Precirix
since 20142.236.309.363
Mandate history
39 people since 2014, 16 in office
- Board
- Day-to-day management
- Statutory auditor
- Other function
- not recently confirmed
- began earlier
| Name | Functions and periods |
|---|---|
| BOS Jasper Marnix |
|
| BOTTI Simone |
|
| MOUMDJIAN (geh. DANDIGUIAN) Sabine Kohar |
|
| Pharmetis Sàrl |
|
| BDO |
|
| QUINZ |
|
| D'HUYVETTER Matthias Bruno Líeven |
|
| DE VOS Jens |
|
| DEVOOGDT Nick Mark |
|
| GROWTH FACTOR |
|
| RAES Geert Mark |
|
| MAJOIE Jérome Jean-Ghislain Hugues |
|
| Hasseltberg |
|
| HASSELTBERG |
|
| BAUDHUIN Jean Louis Marie Clément |
|
| DØSSING Morten Graugaard |
|
| Bos Jasper |
|
| Burkov Ivan |
|
| Cetium AS |
|
| Hansen Camilla Petrycer |
|
| Mesonax Ltd |
|
| Pharmetis |
|
| Steen Marten |
|
| Vlemmix Michaël |
|
| Sabine Dandiguian |
|
| Dimitrios Mantzilas |
|
| Josie Gayton |
|
| Hasseltberg BV |
|
| BAUDHUIN Jean Louis |
|
| HAMMER Ohad |
|
| TAKKE Christina |
|
| Karl Nägler |
|
| DE LEENER Pierre Marie |
|
| Geert RAES |
|
| Jacobus BOONEN |
|
| Jan WILLEMSE |
|
| LAHOUTTE Tony Maurice |
|
| MAJOIE Jérôme |
|
| GROWTH FACTOR |
|
Articles of association
Purpose
Alle activiteiten die verband houden met fundamenteel of toegepast onderzoek alsook de ontwikkeling van alle farmaceutische en/of radiofarmaceutische producten voor therapeutisch…
Full purpose
Alle activiteiten die verband houden met fundamenteel of toegepast onderzoek alsook de ontwikkeling van alle farmaceutische en/of radiofarmaceutische producten voor therapeutisch en diagnostisch gebruik. Alle diensten van onderzoek, experimenten en consulting bestemd voor de medische, farmaceutische en radiofarmaceutische industrie in alle medische en farmaceutische domeinen, zowel therapeutisch als diagnostisch. De ontwikkeling, de exploitatie of de verkoop van medische, farmaceutische en radiofarmaceutische producten voor therapeutisch & diagnostisch gebruik.
Structure & network
Owners and holdings
1 ownerOwners 1
-
3.45%
Holdings 0
No holding stated in the accounts, acts or LEI register we read.
According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
2 connected companiesThe connected companies are in the list below.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, scroll to zoom.
Linked via shared directors
ACTANZA
Shared director
→
AgomAb Therapeutics
Shared director
→
Capital and shareholders
Shareholders according to the acts
After the capital increase
act of 30-11-2017 ↗
- BAUDHUIN Jean Louis 1,134 shares · 112,929.46 EUR
- WILLEMSE Jan 1,134 shares · 112,929.46 EUR
- DE LEENER Pierre Marie 1,134 shares · 112,929.46 EUR
- FONDATION FOURNIER MAJOIE POUR L'INNOVATION (BE 0886.551.096) 568 shares · 56,564.32 EUR
- DEVENYNS Ruth Martine Yvonne 1,030 shares · 102,572.61 EUR
After the capital increase
act of 29-07-2015 ↗
- WILLEMSE Jan Justine Henri
- BAUDHUIN Jean Louis Marie Clément
- ADRINEKA (BE 0885.357.008)
- FONDATION FOURNIER MAJOIE POUR L'INNOVATION (BE 0886.551.096)
The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.
Capital over the years
- 20-01-2026 Capital stated in 2 acts · 21,529,954.30 EUR · 293,607 shares
- 03-03-2022 Capital increase of 9,777,308.89 EUR · to 21,529,954.30 EUR · 133,333 new shares
- 02-10-2020 Capital stated in the act · 11,752,645.41 EUR · 160,274 shares
- 16-07-2020 Capital increase of 4,705,219.45 EUR · to 11,752,645.41 EUR · 64,165 new shares
- 04-12-2018 Capital increase of 4,033,150 EUR · to 7,047,425.96 EUR · 55,000 new shares
- 30-11-2017 Capital increase of 497,925.31 EUR · to 3,014,275.96 EUR
- 16-06-2017 Capital increase of 995,850.65 EUR · to 2,516,350.65 EUR · in cash
- 29-07-2015 Capital increase of 350,000 EUR · to 470,500 EUR · 3,514 new shares
Show 2 older capital entries
- 10-06-2015 Capital increase of 59,000 EUR · to 120,500 EUR · 5,900 new shares
- 24-10-2014 Incorporation · 61,500 EUR · 6,150 shares
Similar companies · same sector, comparable size
PDVT
BE 0803.065.968
Sint-Jans-Molenbeek · Eq €60,671
IDRO
BE 0748.378.754
Antwerpen · Eq €58,491
GDP HEALTH
BE 1017.464.276
Lasne · Eq €56,637
NuStats Lab
BE 1010.533.033
Erpe-Mere · Eq €63,428
IndusFilter
BE 0698.642.894
Gent · Eq €63,549
Of 762 companies in sector 72101 we hold annual accounts for 484. 258 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded15-10-2014
Fiscal year end17-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
72109Other research and development on natural sciences
E-invoicing
Reachable via Peppol
Peppol ID
0208:0564736473
Registered
27-03-2026
The company is no longer active; its Peppol card can remain until its access point withdraws it.
Register as of 28 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.